Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs (2026-02-11)
Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.